NCT00403650View on ClinicalTrials.gov

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions
SarcoidosisPulmonary Arterial Hypertension
Interventions
DRUG

Iloprost

Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
lead

University of Cincinnati

OTHER

NCT00403650 - Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension | Biotech Hunter | Biotech Hunter